Your browser doesn't support javascript.
loading
Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy.
Wu, Hong; Li, Hongyan; Liu, Yiqiang; Liang, Jingchen; Liu, Qianshi; Xu, Zhigang; Chen, Zhongzhu; Zhang, Xia; Zhang, Kun; Xu, Chuan.
Affiliation
  • Wu H; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Ren-min Road, Chengdu, 610042, Sichuan, PR China.
  • Li H; Department of Medical Ultrasound and Central Laboratory, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai, 200072, PR China.
  • Liu Y; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Ren-min Road, Chengdu, 610042, Sichuan, PR China.
  • Liang J; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Ren-min Road, Chengdu, 610042, Sichuan, PR China.
  • Liu Q; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Ren-min Road, Chengdu, 610042, Sichuan, PR China.
  • Xu Z; International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, NO. 319, Red River Avenue, Yong-chuan, 402160, Chongqing, PR China.
  • Chen Z; International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, NO. 319, Red River Avenue, Yong-chuan, 402160, Chongqing, PR China.
  • Zhang X; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), NO. 30, Gao-tan-yan-zheng Street, Chongqing, 400038, PR China.
  • Zhang K; Department of Medical Ultrasound and Central Laboratory, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai, 200072, PR China.
  • Xu C; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center School of Medicine, University of Electronic Science and Technology of China, No.55, Section 4, South Ren-min Road, Chengdu, 610042, Sichuan, PR China.
Bioact Mater ; 13: 223-238, 2022 Jul.
Article in En | MEDLINE | ID: mdl-35224304

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Bioact Mater Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Bioact Mater Year: 2022 Document type: Article